Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 6, 2009, Pages 510-519

  Kobayashi, Hiroyuki ^a   Yasuda, Shinji ^a   Bao, Narentuoya ^a   Iwasa, Masamitsu ^a   Kawamura, Itta ^a   Yamada, Yoshihisa ^a   Yamaki, Takahiko ^a   Sumi, Syohei ^a   Ushikoshi, Hiroaki ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Fujiwara, Takako ^b   Fujiwara, Hisayoshi ^a   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO WOMEN'S UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Infarct size; LV remodeling; Myocardial infarction; Oxytocin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; OXYTOCIN; OXYTOCIN RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; STAT3 PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL SURVIVAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; REPERFUSION INJURY; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD31; BLOOD PRESSURE; CYCLIN D1; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART; HEART RATE; MALE; MATRIX METALLOPROTEINASE 1; MICROVESSELS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; OXYTOCIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; RECEPTORS, OXYTOCIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STROKE VOLUME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 74949089655     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181bfac02     Document Type: Article

References (25)

1. Schriefer JA, Lewis PR, Miller JW. Role of fetal oxytocin in parturition in the rat. Biol Reprod. 1982;27:362-368.
2. Gutkowska J, Jankowski M, Lambert C, et al. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A. 1997;94:11704-11709. (Pubitemid 27451062)
3. Michellni LC, Marcelo MC, Amico J, et al. Oxytocinergic regulation of cardiovascular function: studies in oxytocin-deficient mice. Am J Physiol Heart Circ Physiol. 2003;284:H2269-H2276.
4. Paquin J, Danalache BA, Jankowski M, et al. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci U S A. 2002;99:9550-9555.
5. Matsuura K, Nagai T, Nishigaki N, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem. 2004;279:11384-11391.
6. Detillion CE, Craft TKS, Glasper ER, et al. Social facilitation of wound healing. Psychoneuroendocrinology. 2004;29:1004-1011.
7. Hausenly DJ, Tsang A, Mocanu MM, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971-H976.
8. Xuan YT, Guo Y, Han H, et al. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A. 2001;98: 9050-9055.
9. Stephanou A. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem. 2000;275:10002-10008.
10. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic post-conditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H578-H588.
11. Tsang A, Hausenloy DJ, Mocanu MM, et al. Postconditioning: a form of ''modified reperfusion'' protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95: 230-232.
12. Kobayashi H, Minatoguchi S, Yasuda S, et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res. 2008;79:611-620.
13. Takano H, Manchikalapudi S, Tang XL, et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation. 1998;98:441-449.
14. Lebuffe G, Schumacker PT, Shao ZH, et al. ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. Am J Physiol Heart Circ Physiol. 2003;284:H299-H308.
15. Zhu M, Feng J, Lucchinetti E, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res. 2006;72:152-162.
16. Goldstein P. Controlling cell death. Science. 1997;275:1081-1082.
17. Hattori R, Hernandez TE, Zhu L, et al. An essential role of the antioxidant gene Bcl-2 in myocardial adaptation to ischemia: an insight with antisense Bcl-2 therapy. Antioxid Redox Signal. 2001;3:403-413.
18. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;9:662-670.
19. Asahara T, Takahashi T, Matsuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J. 1999;18:3964-3972. (Pubitemid 29335849)
20. Van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006; 26:716-728.
21. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
22. Reemers EEJM, Cleutjens JPM, Smith JFM, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2002;89:201-210.
23. Spinale FG. Matrix metalloproteinases: regulation and dysregulation on the failing heart. Circ Res. 2002;90:520-530.
24. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation. 2000;102:246-252.
25. Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarct granulocyte colony-stimulating factor treatment. Circulation. 2004;109: 2572-2580.